GE HealthCare Technologies Inc. - Common Stock (GEHC)
64.39
+0.00 (0.00%)
NASDAQ · Last Trade: Apr 15th, 5:58 AM EDT
Detailed Quote
Previous Close
64.39
Open
-
Bid
63.01
Ask
71.74
Day's Range
N/A - N/A
52 Week Range
57.65 - 94.80
Volume
20
Market Cap
-
PE Ratio (TTM)
-
EPS (TTM)
-
Dividend & Yield
0.1200 (0.19%)
1 Month Average Volume
5,430,077
Chart
About GE HealthCare Technologies Inc. - Common Stock (GEHC)
GE HealthCare Technologies Inc. is a leading global medical technology and digital solutions innovator focused on improving patient outcomes through advanced healthcare solutions. The company develops and manufactures a wide range of diagnostic imaging systems, monitoring devices, and healthcare IT services that empower healthcare providers to deliver accurate and efficient patient care. Through its commitment to innovation, GE HealthCare supports clinicians and patients by providing tools that enhance diagnostic capabilities, streamline workflows, and facilitate data-driven decision-making in an increasingly complex healthcare environment. Read More
Cincinnati Children’s and GE HealthCare (Nasdaq: GEHC) will form a strategic research program focused on driving clinical and technical research to advance innovation for pediatric care delivery across modalities, including magnetic resonance imaging (MRI), ultrasound, molecular imaging (MI), and computed tomography (CT). The research program will establish the first pediatric Care Innovation Hub nationwide, representing a new model established by GE HealthCare and Cincinnati Children’s to combine their talents and resources to accelerate the impact of innovation and scientific activities for the benefit of pediatric patients.
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how medical devices & supplies - imaging, diagnostics stocks fared in Q4, starting with Hologic (NASDAQ:HOLX).
GE HealthCare (Nasdaq: GEHC), a leading global healthcare solutions provider, announced the appointment of Jeannette Bankes as president and CEO, Patient Care Solutions, effective May 1, 2025.
Several large-cap stocks, mainly in technology, saw significant declines this week due to macro and supply chain uncertainties. Are they in your portfolio?
Stay tuned for the market movements in the S&P500 index on Friday. Check out the gap up and gap down stocks in the S&P500 index during today's session.
Let's have a look at what is happening on the US markets before the opening bell on Friday. Below you can find the top S&P500 gainers and losers in today's pre-market session.
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the medical devices & supplies - imaging, diagnostics industry, including QuidelOrtho (NASDAQ:QDEL) and its peers.
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at GE HealthCare (NASDAQ:GEHC) and its peers.
GE HealthCare Technologies Inc. (GE HealthCare or the Company) (Nasdaq: GEHC) has completed its acquisition of the remaining 50% stake in Nihon Medi-Physics Co., Ltd (NMP), from Sumitomo Chemical, giving it full ownership. As part of GE HealthCare, NMP can further build on its expertise in developing and manufacturing proprietary and in-licensed radiopharmaceuticals used in single photon emission computed tomography (SPECT) and positron emission tomography (PET) molecular imaging procedures to detect and diagnose disease.
At the American College of Cardiology 2025 meeting, GE HealthCare (Nasdaq: GEHC) will proudly introduce Revolution™ Vibe,i a new computed tomography (CT) system with Unlimited One-Beat Cardiac imaging to deliver consistent, high-quality images for patients, even in challenging cases like atrial fibrillation and heavily calcified coronaries. Combined with the company’s impressive ECG-less Cardiac, TrueFidelity DL, SnapShot Freeze 2, and Effortless Workflow's AI-powered solutions, Revolution Vibe enables fast, accurate diagnoses, a more comfortable patient experience, and more efficient workflows.v
The Board of Directors of GE HealthCare Technologies Inc. (Nasdaq: GEHC) today declared a cash dividend of $0.035 per share of Common Stock for the first quarter of 2025 payable on May 15, 2025 to all shareholders of record as of April 25, 2025.
GE HealthCare (Nasdaq: GEHC) today announced the U.S. launch of Flyrcado™ (flurpiridaz F 18) injection at the 2025 American College of Cardiology (ACC) Annual Scientific Session & Expo, taking place March 29-31 in Chicago. Additionally, the company will showcase new AI-powered innovations, reflecting its strategy to leverage AI to help increase efficiency and enable seamless integration of data across the cardiology care pathway. GE HealthCare has been investing in AI for years and has topped the FDA list of AI-enabled device authorizations for three years in a row with 85 authorizations.i
Over the past six months, GE HealthCare’s stock price fell to $82.47. Shareholders have lost 10.8% of their capital, disappointing when considering the S&P 500 was flat. This might have investors contemplating their next move.
GE HealthCare (Nasdaq: GEHC) announced the launch of Invenia™ Automated Breast Ultrasound (ABUS) Premium, the latest 3D ultrasound offering advanced artificial intelligence (AI) and innovative features to drive faster*, reproducible supplemental screening and streamline exam readings on patients with dense breasts.
NVIDIA Corp. establishes center for accelerated quantum research in Boston, along with collaborations with Alphabet, Google, GE Healthcare, IBM, CrowdStrike & Yum! Brands to drive advancements in AI and transform industries like healthcare and cybersecurity.
GE HealthCare (Nasdaq: GEHC) today announced a collaboration with NVIDIA at GTC 2025, expanding the existing relationship between the two companies to focus on pioneering innovation in autonomous imaging, beginning with autonomous X-ray technologies and autonomous applications within ultrasound.
GE HealthCare (Nasdaq: GEHC) today announced the launch of the AltiX AI.i edition of Mac-Lab™, CardioLab™ and ComboLab™. The AltiX AI.i editions are designed to improve the user experience, elevating workflow in the cardiac catheterization (cath) lab and supporting even the most complex electrophysiology (EP) procedures. These latest editions offer new features that can streamline workflow and enhance interoperability, while upholding strong cybersecurity standards.
